--- title: "Specialty Biotech 13Fs: Vertex, Regeneron, Amgen, Gilead Decoder" type: learn slug: specialty-biotech-13f-vrtx-regn-amgn-decoder canonical_url: https://13finsight.com/learn/specialty-biotech-13f-vrtx-regn-amgn-decoder published_at: 2026-05-16T04:52:31.012Z updated_at: 2026-05-16T04:52:34.740Z author: Sarah Mitchell author_title: Education Editor author_url: https://13finsight.com/authors/sarah-mitchell word_count: 411 locale: en source: 13F Insight --- # Specialty Biotech 13Fs: Vertex, Regeneron, Amgen, Gilead Decoder > Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Amgen, Gilead Sciences, and Moderna anchor US specialty biotech 13F positioning. Pipeline R&D cycles, patent cliff dynamics, M&A pipeline replacement, and emerging cell-and-gene therapy drive distinctive institutional patterns. US specialty biotechnology equities form a distinctive innovation-driven healthcare corner of institutional 13F positioning. Vertex Pharmaceuticals, Regeneron Pharmaceuticals (REGN), Amgen (AMGN), Gilead Sciences (GILD), and Moderna (MRNA) anchor the cohort. Multi-decade pipeline R&D cycles, patent cliff dynamics, M&A pipeline replacement strategies, and emerging cell-and-gene therapy plus mRNA platform technologies drive distinctive institutional patterns. Reading specialty biotech 13F positioning requires understanding the pipeline-replacement framework plus the multi-year platform and patent cycle dynamics.The specialty biotech business modelSpecialty biotech faces four primary economic drivers:Pipeline R&D cycles. Multi-year clinical trial timelines (5-10+ years from discovery to approval) plus regulatory cycles drive long-cycle franchise economics.Patent cliff dynamics. Multi-year branded drug patent expiration produces revenue cliffs as biosimilar competition emerges. Multi-year pipeline replacement determines long-cycle franchise.M&A pipeline replacement. Multi-year M&A activity supplements internal R&D. Vertex's CASGEVY (Crispr partnership), Amgen's Horizon acquisition (2023), Gilead's Immunomedics plus emerging acquisitions drive pipeline depth.Platform technologies. Multi-year cell-and-gene therapy plus mRNA plus emerging RNA editing platform technologies drive multi-decade franchise economics.Major US specialty biotech namesVertex Pharmaceuticals (VRTX)Cystic fibrosis franchise dominance (Trikafta and predecessors) plus emerging CASGEVY (sickle cell, beta thalassemia gene editing with CRISPR Therapeutics) plus pipeline (pain management, kidney disease, type 1 diabetes). Multi-year pipeline diversification thesis.Regeneron Pharmaceuticals (REGN)Eylea (ophthalmology) franchise plus Dupixent (immunology, partnership with Sanofi) plus emerging Libtayo (oncology). Multi-year Eylea biosimilar exposure plus pipeline diversification.Amgen (AMGN)Diversified across oncology (Otezla, Blincyto, Vectibix), inflammation (Enbrel, Tezspire), bone health (Prolia, Xgeva), cardiovascular (Repatha). Multi-year Horizon Therapeutics acquisition expanded rare disease franchise.Gilead Sciences (GILD)HIV franchise (Biktarvy, Descovy) plus oncology (Trodelvy from Immunomedics) plus emerging cell therapy (Yescarta, Tecartus from Kite Pharma). Multi-year strategic transformation toward oncology.Moderna (MRNA)COVID-19 mRNA franchise (Spikevax) plus emerging RSV plus seasonal flu plus combination plus emerging cancer plus rare disease mRNA platforms.How institutional managers position around specialty biotechThree patterns:Pattern 1: Pipeline-platform concentrationVRTX-concentrated growth manager positions reflect cystic fibrosis franchise plus CASGEVY plus pipeline diversification thesis.Pattern 2: M&A-pipeline positioningAMGN-concentrated active manager positions reflect Horizon acquisition plus diversified franchise thesis.Pattern 3: Platform-technology positioningMRNA-concentrated growth manager positions reflect mRNA platform technology thesis.How to read specialty biotech 13F positioningThree rules:Rule 1: Identify pipeline depthEach operator's pipeline depth determines long-cycle franchise economics.Rule 2: Watch FDA milestonesMulti-year FDA approval timelines drive multi-quarter visibility.Rule 3: Cross-check patent expiration calendarPatent cliff timelines drive franchise replacement requirements.What specialty biotech positioning signalsPipeline-platform conviction. Concentrated VRTX positions signal pipeline platform thesis.M&A-pipeline conviction. Concentrated AMGN positions signal M&A pipeline thesis.Platform-technology conviction. Concentrated MRNA positions signal mRNA platform thesis.For real-time tracking of specialty biotech 13F activity, see the institutional signals feed. ## FAQ ### What are the major US specialty biotech companies? Five major US specialty biotech: (1) Vertex Pharmaceuticals (VRTX) — cystic fibrosis dominance plus CASGEVY gene editing plus pipeline; (2) Regeneron Pharmaceuticals (REGN) — Eylea ophthalmology plus Dupixent immunology plus Libtayo oncology; (3) Amgen (AMGN) — diversified oncology, inflammation, bone health, cardiovascular plus Horizon rare disease; (4) Gilead Sciences (GILD) — HIV plus oncology plus cell therapy; (5) Moderna (MRNA) — COVID-19 mRNA plus emerging platforms. ### Why is Vertex's cystic fibrosis franchise dominant? Vertex operates effective monopoly in cystic fibrosis (CF) treatment through CFTR modulator therapies (Trikafta plus predecessors). Trikafta treats approximately 90% of CF patient population with CFTR-amenable mutations. Multi-decade CF research investment plus regulatory pathway plus genetic understanding produced unique franchise position. Emerging treatment areas (pain, kidney, type 1 diabetes) plus CASGEVY diversify pipeline. ### What is CASGEVY gene editing? CASGEVY (exagamglogene autotemcel) is the first FDA-approved CRISPR/Cas9 gene editing therapy, approved December 2023 for sickle cell disease plus beta thalassemia. CASGEVY was developed jointly by Vertex plus CRISPR Therapeutics. Multi-year commercial ramp limited by complexity of treatment process. CASGEVY plus emerging gene editing applications drive long-cycle franchise. Concentrated VRTX positions partially reflect this thesis. ### How do patent cliffs affect specialty biotech? Multi-year branded biotech drug patent expiration produces revenue cliffs as biosimilar competition emerges. Major recent cliffs include Humira (AbbVie 2023), Stelara (Johnson & Johnson 2024), Eylea (Regeneron 2024-2025 biosimilar competition emerging). Multi-year pipeline replacement determines long-cycle franchise. Multi-year M&A activity supplements internal R&D. Reading patent expiration calendar plus pipeline depth drives institutional positioning. ### What is Amgen's Horizon Therapeutics acquisition? Amgen acquired Horizon Therapeutics for $28.3 billion in 2023 expanding rare disease franchise. Horizon's Tepezza (thyroid eye disease) plus Krystexxa (gout) plus emerging rare disease pipeline strengthened Amgen rare disease positioning. Multi-year integration plus emerging launches plus broader rare disease focus drive franchise diversification beyond traditional oncology plus inflammation focus. Concentrated active manager AMGN positions reflect Horizon thesis. ### What signals specialty biotech cycle inflections? Four signals: (1) major FDA approval milestones for pipeline candidates; (2) Phase 3 clinical readouts driving valuation step changes; (3) M&A activity reshaping franchise positions; (4) biosimilar competition launches affecting branded drug revenue. Concentrated 13F changes around these signals reveal manager cycle reading. --- Source: 13F Insight — https://13finsight.com/learn/specialty-biotech-13f-vrtx-regn-amgn-decoder Author: Sarah Mitchell — https://13finsight.com/authors/sarah-mitchell Last updated: 2026-05-16T04:52:34.740Z